An interventional study of SQ-Kyrin Transcatheter Edge-to-Edge Valve Repair System in Mitral Regurgitation, sponsored by Shanghai Shenqi Medical Technology Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-10.
Sponsored by Shanghai Shenqi Medical Technology Co., Ltd · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Mitral Valve Insufficiency with a site in China — 44 open to participants now, 46 under way, none of them phase 3. Mitral Valve Insufficiency · China.
Among the 57 studies in Mitral Valve Insufficiency with a site in China, this one is the 34th largest by planned enrollment of the 40 interventional ones that give a count, is one of 7 that started in 2021, is one of 36 with no phase, reaches primary completion later than 0 of the 45 other live ones, and was the 9th registered.
471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.
Browse Mitral Valve Insufficiency studies →44 of the 57 studies in Mitral Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18+
Beijing Anzhen Hospital · Sites in China
Ages 18+
Mitrassist Lifesciences Limited Co., Ltd. · Sites in China
Ages 18+
Shanghai HeartEpoch Medical Technology Co., Ltd · Sites in China
Ages 60+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 69 across 280 interventional studies indexed under Mitral Valve Insufficiency.
Median enrollment 127 across the 40 interventional studies, 1,000 across the 17 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 57 have an industry lead sponsor. The 10 most frequent:
Shanghai Shenqi Medical Technology Co., Ltd is the lead sponsor of 10 studies on the registry; 5 are open to participants now.
Shanghai Shenqi Medical Technology Co., Ltd has 4 studies filed under Mitral Valve Insufficiency — fewer than ten, so there is no comparison to draw.
8 of the studies in Mitral Valve Insufficiency with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06162780Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityTEER for Severe DMR of Low to Intermediate Surgery Risk | 2026-12 |
| NCT07632794Mi ChenArtificial Intelligence Assisting Transcatheter Mitral Edge-to-Edge Repair | 2026-12-31 |
| NCT05595187Nanjing Medical UniversityConcomitant Tricuspid Repair in Patients With Left Heart Surgery | 2026-12-31 |
| NCT07243158Hangzhou Valgen Medtech Co., LtdRandomized Controlled Study of Dragonfly System for Functional Mitral Regurgitation | 2027-06-30 |
| NCT06883864Beijing Anzhen HospitalEfficacy and Safety of Catheter abLation in patiEnts With seVere mitrAl regurgiTation and pErsistent Atrial Fibrillation: a Randomized Controlled Trial | 2027-08-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 57 studies in Mitral Valve Insufficiency with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A feasibility study to evaluate the effectiveness and safety of the SQ-Kyrin Transcatheter Edge-to-Edge Valve Repair System for the treatment of moderate-to-severe mitral regurgitation in patients with high surgical risk.
This is a prospective, multicenter, single-arm observation, feasibility clinical study that plans to enroll a total of not less than 10 and not more than 30 patients, adopts the post-op immediate technical success rate as the primary endpoint, and uses the all-cause mortality at 30 days post-op, incidence of serious adverse event at 30 days post-op, device success rate at 30 days post-op, and procedural success rate at 30 days post-op as secondary endpoints to evaluate the effectiveness, safety, and feasibility of the Transcatheter Edge-to-Edge Valve Repair System of Shanghai Shenqi Medical Technology Co., Ltd. in clinical use and preliminarily evaluate the product's performance. A phasic study report (for phasic data summary and analysis) will be issued after completion of the 30-day postoperative follow-up to evaluate the effectiveness, safety, and feasibility of the device and apply for clinical studies before official registration and marketing. In the meantime, patients enrolled will continue to be followed up for 6 months and 1-5 years post-op to evaluate the long-term effect of the mitral valve repair system.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with high or prohibitive risk for conventional open thoracic surgery as defined by STS risk scoring result; subjects who are judged as not tolerating mitral valve surgery due to STS procedural mortality risk ≥ 8% for mitral valve replacement or presence of any of the following risk factors:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental group is allocated to use the transcatheter edge-to-edge valve repair system of Shanghai Shenqi Medical Technology Co., Ltd.
Device: SQ-Kyrin Transcatheter Edge-to-Edge Valve Repair System
Transesophageal echocardiography-guided, implantable mitral valve clip repair system
Incidence of acute procedural success
Must meet all the four items:1)no procedural mortality; 2)success in delivery and retrieval of the device delivery system; 3)successful deployment and accurate positioning of the device; 4)no emergency surgery or reintervention related to the device or surgical approach
Time frame: Immediate postoperative
All-cause mortality
Death from any cause
Time frame: 1 month
Incidence of serious adverse event(SAE)
If the adverse event meets any of the criteria below, it is regarded as a serious adverse event (SAE): 1) results in death; 2) is life threatening, results in illness or injury; 3) requires inpatient hospitalization or prolongation of existing hospitalization; 4) results in a persistent or significant disability/incapacity; 5) results in a congenital anomaly/birth defect, fetal death, fetal distress; 6) results in medical or surgical intervention to prevent permanent impairment to body structure or a body function; 7) an important medical event that may not result in death, be life-threatening, or require hospitalization but may be considered serious when, based upon appropriate medical judgment, may jeopardize the patient or subject and/or may require intervention to prevent one of the outcomes listed in this definition.
Time frame: 1 month
Device success rate
Definition of device success(must meet all the four items) :1) No procedural mortality or stroke;2) Proper deployment and positioning of the device;3) No emergency surgery or reintervention related to the device or surgical approach;4) The implanted mitral valve repair system achieves the following safety and effectiveness indicators: * No evidence of structural or functional abnormality * No device-related technical failure or complication * Significant functional improvement after valve repair, without significant stenosis (post-op EOA ≥ 1.5 cm2 and transvalvular pressure gradient \< 5 mmHg/valve regurgitation ≤ Grade 2+/no device-related hemolysis)
Time frame: 1 month
Procedural success rate
Definition of procedural success(must meet the two items):1) Device success;2) Absence of the following severe complications: death; stroke; life-threatening hemorrhage; severe vascular complications; secondary severe organic heart diseases (e.g.: aortic dissection, left atrium/auricle rupture, left ventricular outflow tract obstruction, etc.); Grade II-III and above renal insufficiency; myocardial infarction or coronary ischemia requiring percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG); severe hypotension, heart failure, respiratory failure requiring use of high-dose vasoactive medications/mechanical acids; any valve-related dysfunctions, including repair device detachment (single or two valve leaflets)/embolism/device-related autologous mitral valve damage/other conditions requiring second intervention.
Time frame: 1 month
Started Apr 2021 (actual). Primary completion is estimated for Oct 2022, 18 months after the start.
Of 91 industry-sponsored interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 144. This study's planned 18 months is below that.
Counting every sponsor, half of 144 studies reached it within 56 months; a quarter within 25 and three quarters within 108.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Shenqi Medical Technology Co., Ltd